ScoreWhy is Bal Pharma Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 9.44%
- Poor long term growth as Net Sales has grown by an annual rate of 4.43% and Operating profit at 5.67% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 5.00 times
2
Flat results in Jun 26
- CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 7.21 cr
3
With ROCE of 9, it has a Attractive valuation with a 1.4 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 28.84%, its profits have risen by 0.7% ; the PEG ratio of the company is 25.2
4
Majority shareholders : Promoters
5
Market Beating Performance
- Even though the market (BSE500) has generated negative returns of -0.31% in the last 1 year, the stock has been able to generate 28.84% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Bal Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Bal Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Bal Pharma
28.84%
0.71
40.42%
Sensex
-7.81%
-0.58
13.43%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
4.43%
EBIT Growth (5y)
5.67%
EBIT to Interest (avg)
1.26
Debt to EBITDA (avg)
4.78
Net Debt to Equity (avg)
1.83
Sales to Capital Employed (avg)
1.52
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
26.48%
Pledged Shares
0
Institutional Holding
0.15%
ROCE (avg)
9.59%
ROE (avg)
8.24%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
25
Industry P/E
37
Price to Book Value
2.21
EV to EBIT
14.78
EV to EBITDA
9.82
EV to Capital Employed
1.43
EV to Sales
0.99
PEG Ratio
25.21
Dividend Yield
1.05%
ROCE (Latest)
8.96%
ROE (Latest)
7.64%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
DEBT-EQUITY RATIO(HY)
Lowest at 1.94 times
NET SALES(Q)
At Rs 88.62 cr has Grown at 34.54%
-1What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 7.21 cr
Loading Valuation Snapshot...
Here's what is working for Bal Pharma
Net Sales - Quarterly
Highest at Rs 88.62 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 88.62 cr has Grown at 34.54%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Debt-Equity Ratio - Half Yearly
Lowest at 1.94 times
in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Bal Pharma
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 7.21 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
